Cometriq (cabozantinib) is a prescription medicine used to treat people with medullary thyroid cancer (MTC) which has spread to other parts of the body (called metastatic MTC).
Manufacturer : Exelixis, Inc.
Strengths available : 100mg & 140mg
Form : Capsules
FDA Approved : US FDA Approved
Date of Approval : November 29th, 2012
Storage : Store at room temperature between 20° C – 25° C
Do NOT substitute COMETRIQ capsules with cabozantinib tablets.
The recommended daily dose of COMETRIQ is 140 mg (one 80-mg and three 20-mg capsules). Do not administer COMETRIQ with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Continue treatment until disease progression or unacceptable toxicity occurs.
Swallow COMETRIQ capsules whole. Do not open COMETRIQ capsules.
Do not take a missed dose within 12 hours of the next dose.
Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking COMETRIQ.
Serious side effects may be Blood clots, Stroke, Heart attack, and Chest pain , Swelling or pain in your arms or legs, Shortness of breath, Feel lightheaded or faint, Sweating more than usual, numbness or weakness of your face, arm or leg, especially on one side of your body, sudden confusion, trouble speaking or understanding, sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance or coordination, a sudden severe headache
7 x 20 mg or 7 x 80 mg Capsules
3S Corporation is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of COMETRIQ Cabozantinib Capsules based in India - To buy COMETRIQ Cabozantinib Capsules or know its cost price contact us here.
We supply & sell COMETRIQ Cabozantinib Capsules for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.